Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.

Sordella R, Bell DW, Haber DA, Settleman J.

Science. 2004 Aug 20;305(5687):1163-7. Epub 2004 Jul 29.

2.

Review. EGFR mutations in non-small cell lung cancer--clinical implications.

Charpidou A, Blatza D, Anagnostou V, Syrigos KN.

In Vivo. 2008 Jul-Aug;22(4):529-36. Review. Erratum in: In Vivo. 2008 Nov-Dec;22(6):886. Anagnostou, Elsa [corrected to Anagnostou, Valsamo].

3.

EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.

Takeuchi K, Ito F.

FEBS J. 2010 Jan;277(2):316-26. doi: 10.1111/j.1742-4658.2009.07450.x. Epub 2009 Nov 18. Review.

4.

Targeting apoptosis pathways in lung cancer.

Pore MM, Hiltermann TJ, Kruyt FA.

Cancer Lett. 2013 May 28;332(2):359-68. doi: 10.1016/j.canlet.2010.09.012. Epub 2010 Oct 25. Review.

PMID:
20974517
5.

Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer.

Arteaga CL, Khuri F, Krystal G, Sebti S.

Semin Oncol. 2002 Feb;29(1 Suppl 4):15-26. Review.

PMID:
11894010
6.

Role of protein kinase B-dependent signaling in lung tumorigenesis.

Kurie JM.

Chest. 2004 May;125(5 Suppl):141S-4S. Review.

PMID:
15136468
7.

Ligand-Independent EGFR Signaling.

Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA.

Cancer Res. 2015 Sep 1;75(17):3436-41. doi: 10.1158/0008-5472.CAN-15-0989. Epub 2015 Aug 17. Review.

Supplemental Content

Support Center